- Home
- DWTX vs GLTO Comparison
DWTX vs GLTO Comparison
Compare DWTX & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DWTX
- GLTO
- Stock Information
- Founded
- DWTX 2012
- GLTO 2011
- Country
- DWTX United States
- GLTO Denmark
- Employees
- DWTX N/A
- GLTO N/A
- Industry
- DWTX
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- DWTX
- GLTO Health Care
- Exchange
- DWTX NYSE
- GLTO Nasdaq
- Market Cap
- DWTX 5.9M
- GLTO 6.5M
- IPO Year
- DWTX N/A
- GLTO 2020
- Fundamental
- Price
- DWTX $5.66
- GLTO $2.85
- Analyst Decision
- DWTX Strong Buy
- GLTO Buy
- Analyst Count
- DWTX 1
- GLTO 1
- Target Price
- DWTX $10.00
- GLTO $10.00
- AVG Volume (30 Days)
- DWTX 2.4M
- GLTO 50.5K
- Earning Date
- DWTX 05-14-2025
- GLTO 05-06-2025
- Dividend Yield
- DWTX N/A
- GLTO N/A
- EPS Growth
- DWTX N/A
- GLTO N/A
- EPS
- DWTX N/A
- GLTO N/A
- Revenue
- DWTX N/A
- GLTO N/A
- Revenue This Year
- DWTX N/A
- GLTO N/A
- Revenue Next Year
- DWTX N/A
- GLTO N/A
- P/E Ratio
- DWTX N/A
- GLTO N/A
- Revenue Growth
- DWTX N/A
- GLTO N/A
- 52 Week Low
- DWTX $1.62
- GLTO $2.01
- 52 Week High
- DWTX $29.28
- GLTO $18.50
- Technical
- Relative Strength Index (RSI)
- DWTX N/A
- GLTO 46.24
- Support Level
- DWTX N/A
- GLTO $2.36
- Resistance Level
- DWTX N/A
- GLTO $2.86
- Average True Range (ATR)
- DWTX 0.00
- GLTO 0.29
- MACD
- DWTX 0.00
- GLTO 0.09
- Stochastic Oscillator
- DWTX 0.00
- GLTO 98.59
About DWTX DOGWOOD THERAPEUTICS INC
Dogwood Therapeutics Inc formerly Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM) and Long-COVID (LC). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.